Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP)

Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP) - Perhexiline maleate treatment for FOP

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019348

Enrollment

Registered

2015-10-14

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fibrodysplasia ossificans progressiva

Interventions

oral administration of perhexiline maleate for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who presents classic features of FOP, and who have R206H mutation in the ACVR1/ALK2 gene.

Exclusion criteria

Exclusion criteria: Skeletally immature patients

Design outcomes

Primary

Measure	Time frame
Total bone volume before the intervention, at the end of medication, and at the end of the study	—

Secondary

Measure	Time frame
serum alkaline phosphatase and osteocalsin concentration	—

Countries

Japan

Contacts

Public ContactHiroshi Kitoh

Nagoya University Graduate School of Medicine Orthopaedic Surgery

hkitoh@med.nagoya-u.ac.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026